03.06.2019 • NewsBayerDede WillamsFoundation Medicine

Bayer and Foundation Medicine in Oncology Pact

Bayer and Foundation Medicine in Oncology Link
Bayer and Foundation Medicine in Oncology Link

Germany’s Bayer and Foundation Medicine of the US have announced plans for a global collaboration on development and commercialization of NGS-based companion diagnostics.

The joint effort will focus on multiple oncology drug candidates and approved therapies developed by Bayer, while leveraging Foundation Medicine’s full portfolio of tests, including FoundationOneCDx.

First project will be to develop a companion diagnostic for Bayer’s Vitravki (Larotrectinib), the first and up to now only TRK inhibitor approved by the US Food and Drug Administration (FDA) for patients with TRK fusion cancer across all solid tumors. Larotrectinib is under review in other markets.

With the NGS-based companion diagnostic tests, researchers aim to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies.

 “The development of a companion diagnostic for Larotrectinib, and our broader collaboration with Foundation Medicine, is an important step forward toward expanding access to testing and identifying the right treatment options for patients with cancer,” said  Robert LaCaze, head of the Oncology strategic business unit at Bayer.

Explaining the rationale behind the decision to collaborate with Bayer, Cindy Perettie, Foundation Medicine’s CEO, said it is “imperative that patients receive broad comprehensive genomic profiling at initial diagnosis of late stage cancer to determine if they are eligible for these medicines.”

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.